Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396042 · ClinicalTrials.gov registry record
Natural History Study of CEP290-Related Retinal Degeneration
A clinical trial of Eye Diseases and Retinal Disease, sponsored by Editas Medicine.
- Completed
- Registry status
- 26
- Enrollment target
- 7
- Study locations
NCT03396042: Completed study of Eye Diseases and Retinal Disease, sponsored by Editas Medicine.
NCT03396042 is a study of Eye Diseases and Retinal Disease that has completed, run by Editas Medicine. The registered enrollment target is 26 participants, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03396042, a study of Eye Diseases and Retinal Disease, has completed, sponsored by Editas Medicine.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
- 7
- Study locations
Study Summary
A prospective natural history study with systematic assessments and uniform follow-up to provide a high-quality dataset for assisting in the design of future clinical treatment trials involving patients with CEP290-related retinal degeneration caused by the common intron 26 mutation.
Primary Outcome
To prospectively characterize CEP290-related retinal degeneration and the clinical phenotype of patients with either compound heterozygous or homozygous intron 26 c.2991+1655A\>G mutations
Conditions Studied
Study Locations (7)
Other
- Universite Pierre et Marie Curie - Paris
- Universitaetsklinikum Giessen and Marburg GmbH - Giessen
Florida
- Bascom Palmer Eye Institute - Miami
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Michigan
- W.K. Kellogg Eye Center - Ann Arbor
Oregon
- Casey Eye Institute - OHSU - Portland
Gelderland
- Radboud Universitair Medisch Centrum - Nijmegen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-12-17 |
| Est. Completion | 2022-05-06 |
What the finished NCT03396042 record still lists
NCT03396042 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 741,302-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower).
The record links to 8 conditions, with Eye Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT03396042 lists 7 locations in 6 states (Other, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT03396042 about?
NCT03396042 is a clinical study titled "Natural History Study of CEP290-Related Retinal Degeneration". A prospective natural history study with systematic assessments and uniform follow-up to provide a high-quality dataset for assisting in the design of future clinical treatment trials involving patients with CEP290-related retinal degeneration caused by the common intron 26 mutation.
What is the current status of trial NCT03396042?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2017-12-17. Estimated completion is 2022-05-06.
What conditions does trial NCT03396042 study?
This clinical trial studies the following conditions: Eye Diseases, Retinal Disease, Retinal Degeneration, Eye Diseases, Hereditary, Blindness.
Who is sponsoring clinical trial NCT03396042?
This trial is sponsored by Editas Medicine, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03396042 being conducted?
This trial has 7 study locations across Florida, Massachusetts, Michigan, Oregon, Gelderland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03396042's enrollment target sits among peer trials
26 23rd of 27 higher than 5 of 27 other Eye Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eye Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adaptive Optics Retinal Imaging
RECRUITING
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
RECRUITING · NA
-
IRIS Registry: Intelligent Research in Sight Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI